Review anchor
Human immunodeficiency virus 1
ORGANISM · Human immunodeficiency virus 1
As of 2026-09-13
Evidence Snapshot
Human immunodeficiency virus 1
CHEMBL378
ORGANISM
Human immunodeficiency virus 1
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Human immunodeficiency virus 1 as ChEMBL target CHEMBL378. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL378
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Human immunodeficiency virus 1 matters
Human immunodeficiency virus 1 is reviewed as Human immunodeficiency virus 1; the current evidence base includes 103 approved drugs, 27506 compounds, and 9288 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Human immunodeficiency virus 1
Human immunodeficiency virus 1
Review this target as Human immunodeficiency virus 1.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 103 approved drugs, 27506 compounds, and 9288 assays for this target. The dominant activity type is EC50. CHEMBL57 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL57 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
103 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Human immunodeficiency virus 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
27506
Total Compounds
9288
Total Assays
103
Approved Drugs
IC50: 14324.0, KI: 6.0, EC50: 38512.0, KD: 11.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL57
|
11.0 | EC50 | Approved |
|
|
No preferred name
CHEMBL2315350
|
11.0 | EC50 | — |
|
|
No preferred name
CHEMBL4873511
|
11.0 | EC50 | — |
|
|
No preferred name
CHEMBL70663
|
11.0 | EC50 | Clinical |
|
|
No preferred name
CHEMBL1643090
|
10.9 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MAVORIXAFOR
CHEMBL518924
|
2024 |
|
|
LENACAPAVIR
CHEMBL4594438
|
2022 |
|
|
CABOTEGRAVIR
CHEMBL2403238
|
2021 |
|
|
BICTEGRAVIR
CHEMBL3989866
|
2018 |
|
|
DORAVIRINE
CHEMBL2364608
|
2018 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
TENOFOVIR ALAFENAMIDE FUMARATE
CHEMBL2364637
|
2015 |
|
|
TENOFOVIR ALAFENAMIDE
CHEMBL2107825
|
2015 |
|
|
PALBOCICLIB
CHEMBL189963
|
2015 |
|
|
ASUNAPREVIR
CHEMBL2105735
|
2014 |
|
|
MILTEFOSINE
CHEMBL125
|
2014 |
|
|
DOLUTEGRAVIR
CHEMBL1229211
|
2013 |
|
|
DOLUTEGRAVIR SODIUM
CHEMBL1213165
|
2013 |
|
|
TOFACITINIB
CHEMBL221959
|
2012 |
|
|
ELVITEGRAVIR
CHEMBL204656
|
2012 |
|
|
RILPIVIRINE
CHEMBL175691
|
2011 |
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
|
|
INGENOL MEBUTATE
CHEMBL1863513
|
2010 |
|
|
ROMIDEPSIN
CHEMBL343448
|
2009 |
|
|
ETRAVIRINE
CHEMBL308954
|
2008 |
|
|
PLERIXAFOR
CHEMBL18442
|
2008 |
|
|
RALTEGRAVIR
CHEMBL254316
|
2007 |
|
|
MARAVIROC
CHEMBL256907
|
2007 |
|
|
RALTEGRAVIR POTASSIUM
CHEMBL518520
|
2007 |
|
|
DARUNAVIR
CHEMBL1323
|
2006 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
TIPRANAVIR
CHEMBL222559
|
2005 |
|
|
ENTECAVIR
CHEMBL5314362
|
2005 |
|
|
ATAZANAVIR
CHEMBL1163
|
2003 |
|
|
EMTRICITABINE
CHEMBL885
|
2003 |
|
|
ENFUVIRTIDE
CHEMBL525076
|
2003 |
|
|
ADEFOVIR DIPIVOXIL
CHEMBL922
|
2002 |
|
|
TENOFOVIR DISOPROXIL
CHEMBL1538
|
2001 |
|
|
TENOFOVIR DISOPROXIL FUMARATE
CHEMBL1486
|
2001 |
|
|
LOPINAVIR
CHEMBL729
|
2000 |
|
|
SIROLIMUS
CHEMBL413
|
1999 |
|
|
AMPRENAVIR
CHEMBL116
|
1999 |
|
|
EFAVIRENZ
CHEMBL223228
|
1998 |
|
|
ABACAVIR SULFATE
CHEMBL4303288
|
1998 |
|
|
ABACAVIR
CHEMBL1380
|
1998 |
|
|
DELAVIRDINE MESYLATE
CHEMBL929
|
1997 |
|
|
NELFINAVIR
CHEMBL584
|
1997 |
|
|
DELAVIRDINE
CHEMBL593
|
1997 |
|
|
INDINAVIR SULFATE
CHEMBL1735
|
1996 |
|
|
RITONAVIR
CHEMBL163
|
1996 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
NEVIRAPINE
CHEMBL57
|
1996 |
|
|
SAQUINAVIR
CHEMBL114
|
1995 |
|
|
LAMIVUDINE
CHEMBL141
|
1995 |
Source Header